New drug cocktail aims to stall pancreatic cancer after chemo

NCT ID NCT06747845

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II study tests whether a combination of two drugs, niraparib and ipilimumab, can slow tumor growth in people with metastatic pancreatic cancer whose disease has not worsened after platinum-based chemotherapy. About 68 participants will be randomly assigned to receive either the new combo or standard chemotherapy. The main goal is to see how long the cancer stays under control and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib and ipilimumab
What this could lead to: If successful, this combination could offer a new maintenance option to delay tumor growth in metastatic pancreatic cancer.
What could go wrong: This is a small phase II trial, so results may not confirm benefit. The combination may cause significant side effects and may not work better than standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA METASTATIC

Contacts and locations

Locations

Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
University of Pennsylvania, Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.